CN Patent

CN101810583B — Hiv融合抑制剂缓释微球

Assigned to Individual · Expires 2013-09-11 · 13y expired

What this patent protects

本发明公开了一种HIV融合抑制剂缓释微球。HIV融合抑制剂选自恩夫韦肽、西夫韦肽、艾博卫泰。HIV融合抑制剂缓释微球采用生物可降解聚合物作为微球基质，粒径为1～1000微米，可用于注射，在体内可缓释0.5～3个月或更长时间。本发明还公开了HIV融合抑制剂缓释微球的制备方法。

USPTO Abstract

本发明公开了一种HIV融合抑制剂缓释微球。HIV融合抑制剂选自恩夫韦肽、西夫韦肽、艾博卫泰。HIV融合抑制剂缓释微球采用生物可降解聚合物作为微球基质，粒径为1～1000微米，可用于注射，在体内可缓释0.5～3个月或更长时间。本发明还公开了HIV融合抑制剂缓释微球的制备方法。

Drugs covered by this patent

leuprolide-mesylate (LEUPROLIDE MESYLATE)

Patent Metadata

Patent number: CN101810583B
Jurisdiction: CN
Classification: —
Expires: 2013-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.